Orchestra BioMed Holdings, Inc. (OBIO) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$5.49

From 52W high−11.02%

Volume226543.00

Market cap$339.59M

P/E (TTM)—

P/S (TTM)10.6x

Div yield—

Key dataOct 19, 2026

Open

$5.49

From 52W high

−11.02%

Volume

226543.00

Market cap

$339.59M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.4x

P/E (TTM)

—

RSI (14)

49.0

MomentumView details →

1D Return

+3.67%

YTD Return

+37.06%

SummaryUpdated Jun 1, 2026

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) is a biomedical innovation company founded in 2020 and based in New Hope, Pennsylvania. The company went public on August 4, 2020, and operates as a development-stage biotechnology firm focused on creating medical devices and therapies for cardiovascular and other critical health conditions. Orchestra BioMed has established strategic partnerships with major medical device companies including Medtronic and Terumo Corporation to advance its product pipeline through clinical development and eventual commercialization.

Ask drillr about Orchestra BioMed Holdings, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−5.4x

EV/Sales

9.7x

P/S (TTM)

10.6x

P/B (TTM)

11.5x

ProfitabilityView details →

Gross Margin

99.32%

Net Margin

−184.60%

EBITDA Margin

−178.56%

ROE (TTM)

−200.64%

ROA (TTM)

−51.02%

Asset Turnover

0.30x

GrowthView details →

Revenue YoY

+986.14%

EPS YoY

+45.60%

FCF YoY

+1.01%

Revenue CAGR 3Y

+111.62%

EPS CAGR 3Y

+33.13%

EBITDA YoY

+19.37%

MomentumView details →

1D Return

+3.67%

YTD Return

+37.06%

1Y Return

+45.84%

RSI (14)

49.0

vs 50D SMA

+2.78%

vs 200D SMA

+27.00%

Capital & dividendView details →

Debt/Equity

2.41x

Current Ratio

8.26x

Quick Ratio

8.24x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.38

EPS Surprise

3.06%

Beats (12Q)

8/12

Next Q EPS Est

−$0.41

Avg Surprise (4Q)

47.84%

Rev Surprise

−36.10%

Financials snapshotView financials →

Revenue (TTM)

31.98M

Net Income (TTM)

−59.03M

Op. CF (TTM)

−58.32M

Next earningsNov 9, 2026 →

Latest newsMore news →

Orchestra BioMed Holdings, Inc. (OBIO) shares jumped 5.2% in the previous session on above-average trading volume.29d ago

Orchestra BioMed announced that its investigational AVIM Therapy will be featured in two sessions at HRX Live 2026, the Heart Rhythm Society's annual meeting in Atlanta, Georgia on September 18-20, 2026.34d ago

Similar companies

Relmada Therapeutics, Inc.RLMD Nautilus Biotechnology, Inc.NAUT Enanta Pharmaceuticals, Inc.ENTA Atea Pharmaceuticals, Inc.AVIR Galectin Therapeutics Inc.GALT Turn Therapeutics Inc.TTRX Find similar companies →

Latest newsMore news →

Orchestra BioMed Holdings, Inc. (OBIO) shares jumped 5.2% in the previous session on above-average trading volume.29d ago Orchestra BioMed announced that its investigational AVIM Therapy will be featured in two sessions at HRX Live 2026, the Heart Rhythm Society's annual meeting in Atlanta, Georgia on September 18-20, 2026.34d ago